Volume : 12, Issue : 01, January – 2025
Title:
DESIGN, DEVELOPMENT AND CHARACTERIZATION OF MATRIX TABLET CONTAINING DEXAMETHASONE
Authors :
Ranjeet Kumar, Naveen Gupta, Dharmendra Singh Rajput
Abstract :
The oral route is considered to be most convenient for administration of drugs to patients. Colonic drug delivery is a relatively recent approach to the treatment of diseases such as ulcerative colitis, Crohn’s disease and irritable bowel syndrome. Such local treatment has the advantage of requiring smaller drug quantities, possibly leading to a reduced incidence of side effects and drug interactions. Inflammatory bowel disease (IBD) is a general term for group of chronic inflammatory disorders of unknown etiology involving the gastrointestinal tract. Since there are no pathognomonic features or specific diagnostic tests, in a strict sense, these disorders remain diagnoses of exclusion. Their features are sufficiently characteristic. However, to permit accurate diagnosis in the majority of cases, chronic IBD may be divided into two major groups chronic non-specific ulcerative colitis and Crohn’s disease. Matrix tablets, though release a minimal percent of the drug in stomach and small intestine, are the choice for colon-targeting of drugs as their preparation involves less processing variables and are manufactured by direct compression with conventional tableting facilities. It is clear from these results that DXCT2 could target dexamethasone to colon because as it released almost the entire quantity at the end of 24 h of study. The DXCT3 tablets are also considered as potential formulations for targeting of dexamethasone to colon because of the fact that the human caecal contents would be far more rich in enzymatic activity than what was used in the present study. However, the relative potential of formulation DXCT2 and DXCT3 need to be evaluated in human volunteers.
Keywords: Inflammatory bowel disease, ulcerative colitis, crohnís disease, dexamethasone, colon targeted drug delivery
Cite This Article:
Please cite this article in press Ranjeet Kumar et al., Design, Development And Characterization Of Matrix Tablet Containing Dexamethasone.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
1. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci [Serial Online] 2003;6(1):500-6. Available fromURL:http://www.ualberta.ca/~csps
2. Wong D, Larrabee S, Clifford K, Tremblay J, Friend DR. USP Dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J Control Release 1997;47:173-9.
3. Srinath A, Pandit JK, “Alternate Polyelectrolyte Coating of Chitosan Beads for Extending Drug Release”, Drug Delvery, 2008, 15, 193-199.
4. Patel NV, Patel JK, Shah SH, Patel JJ, “Design, development and in vitro evaluation of mesalamine tablets containing pectin and chitosan for colon-specific drug delivery”, International Journal of Research Pharmceutical Science, 2010, 1, 94-102.
5. Podolsky DK, “Inflammatory bowel disease”, N Engl Journal Med, 2004, 347, 417-422.
6. Jain SK, Chourasia M, Dengre R, “Azo polymers for colon targeted drug delivery”, Indian Journal Pharm Science, 2005, 67, 1, 43-50.
7. Akhgari A, Farahmand F, Afrasiabi Garekani H, Sadeghi F, Vandamme TF, “Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery”, European Journal Pharmaceutical Science, 2006, 28, 307-314.
8. Ding X, Alani AW, Robinson JR, In Extended-Release and Targeted Drug Delivery Systems. In: Bringer P, Gupta PK, Felton KL, editors. Remington: The Science And Practice of Pharmacy. 21st edition; Baltimore: Lippincott Williams & Wilkins, USA; 2005, pp 939.
9. Fellermann K, Stange EF, “Defensins – innante immunity at the epithelial frontier”, European Journal Gastroenterology Hepatology, 2001, 13, 771- 5.
10. Cummings JH, Jenkins DJA, Wiggins HS, “Measurement of the mean transit time of dietary residue through the human gut”, Gut, 1976, 17, 210-18.
11. Jain A, Gupta Y, Jain SK, “Potential of calcium pectinate beads for target specific drug release to colon”, Journal of Drug Targeting, 2007, 15, 285-294.
12. Leopold, C.S, “Coated dosage forms for colon-specific drug delivery”, Pharmaceutical Science Technology Today, 1999, 2, 5, 197-204.
13. Rowe RC, Sheskey PJ, Quinn ME. In Handbook of Pharmaceutical Excipients. 6th Edn; Philippines: PhP APhA Pharmaceutical Press 2009, pp 298-300, 478-480,782-784.
14. Rubinstein A, Friend DR. Specific Delivery to the Gastrointestinal Tract. In: Domb AJ, editor. Polymeric Site-Specific Pharmacotherapy
15. Nasra MA, EL-Massik MA, Naggar VF, “Development of metronidazole colon- specific delivery systems”, Asian Journal of Pharmaceutical Sciences, 2007, 2, 1, 18-28.
16. Singh BN, Kim KH. In Drug Dlivery: Oral Route. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology. 3rd Edn; New York: Informa Healthcare USA, Inc., USA, 2007, pp 1242- 1244.
17. Waugh A, Gran A. In Ross and Wilson: Anatomy and Physiology in Health and Illness. 9th Edn; New York: Churchill Livingstone, 2001, pp 281-30